Skip to main content
Erschienen in: Endocrine 2/2018

31.01.2018 | Original Article

Longitudinal AddiQoL scores may identify higher risk for adrenal crises in Addison’s disease

verfasst von: Gesine Meyer, Maike Koch, Eva Herrmann, Jörg Bojunga, Klaus Badenhoop

Erschienen in: Endocrine | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Several studies have shown a reduced quality of life (QoL) in patients with Addison’s disease (AD), but investigations of QoL over a long-term course are lacking. Adrenal crises (AC) are life-threatening complications in AD. The purpose of this prospective study was to test whether the repeated use of QoL-questionnaires can detect prodromal periods of an AC.

Methods

110 patients with AD were asked to complete the disease specific-QoL questionnaire AddiQoL and a short questionnaire about adverse events once monthly over a period of ten months. AC was defined if at least two of the following symptoms were reported: (a) hypotension, (b) nausea or vomiting, (c) severe fatigue, (d) documented hyponatremia, hyperkalemia, or hypoglycemia, and subsequent parenteral glucocorticoid administration was carried out.

Results

Prevalence of AC was 10.9/100 patient years. AddiQoL scores in patients with AC showed a trend (p = 0,08) to a wider fluctuation over time. Subjective precrises not meeting the criteria for AC were reported by 31 patients who had significantly lower AddiQoL scores (p = 0,018).

Conclusions

These are the first data showing the course of QoL during a period of ten months in patients with AD. Incidence of AC exceeds previous data. Our data show, that subjective precrises in AD associate with lower QoL. AC, as well as precrises affect intraindividual AddiQol-scores over time with a trend to a stronger fluctuation. Longitudinal AddiQol scores and self-reporting of precrises via patient diaries are additional clinical tools to identify higher risk for critical events.
Literatur
1.
Zurück zum Zitat S. Hahner, M. Loeffler, B. Bleicken et al., Epidemiology of adrenal crisis in chronic adrenal insufficiency: the need for new prevention strategies. Eur. J. Endocrinol. 162, 597–602 (2010)CrossRefPubMed S. Hahner, M. Loeffler, B. Bleicken et al., Epidemiology of adrenal crisis in chronic adrenal insufficiency: the need for new prevention strategies. Eur. J. Endocrinol. 162, 597–602 (2010)CrossRefPubMed
2.
Zurück zum Zitat L.C. Smans, E.S. Van der Valk, A.R. Hermus, P.M. Zelissen, Incidence of adrenal crisis in patients with adrenal insufficiency. Clin. Endocrinol. 84, 17–22 (2016)CrossRef L.C. Smans, E.S. Van der Valk, A.R. Hermus, P.M. Zelissen, Incidence of adrenal crisis in patients with adrenal insufficiency. Clin. Endocrinol. 84, 17–22 (2016)CrossRef
3.
Zurück zum Zitat S. Hahner, C. Spinnler, M. Fassnacht, et al., High incidence of adrenal crisis in educated patients with chronic adrenal insufficiency: a prospective study. J. Clin. Endocrinol. Metab. 100, 407–416 (2015)CrossRefPubMed S. Hahner, C. Spinnler, M. Fassnacht, et al., High incidence of adrenal crisis in educated patients with chronic adrenal insufficiency: a prospective study. J. Clin. Endocrinol. Metab. 100, 407–416 (2015)CrossRefPubMed
4.
Zurück zum Zitat G. Meyer, K. Badenhoop, R. Linder, Addison’s disease with polyglandular autoimmunity carries a more than 2.5-fold risk for adrenal crises: German Health insurance data 2010-2013. Clin. Endocrinol. 85, 347–353 (2016)CrossRef G. Meyer, K. Badenhoop, R. Linder, Addison’s disease with polyglandular autoimmunity carries a more than 2.5-fold risk for adrenal crises: German Health insurance data 2010-2013. Clin. Endocrinol. 85, 347–353 (2016)CrossRef
5.
Zurück zum Zitat K. White, W. Arlt, Adrenal crisis in treated Addison’s disease: a predictable but under-managed event. Eur. J. Endocrinol. 162, 115–120 (2010)CrossRefPubMed K. White, W. Arlt, Adrenal crisis in treated Addison’s disease: a predictable but under-managed event. Eur. J. Endocrinol. 162, 115–120 (2010)CrossRefPubMed
6.
Zurück zum Zitat T.H. Puar, N.M. Stikkelbroeck, L.C. Smans et al., Adrenal crisis: still a deadly event in the 21st century. Am. J. Med. 129(339), e1–e9 (2016) T.H. Puar, N.M. Stikkelbroeck, L.C. Smans et al., Adrenal crisis: still a deadly event in the 21st century. Am. J. Med. 129(339), e1–e9 (2016)
7.
Zurück zum Zitat B. Bleicken, S. Hahner, M. Loeffler et al., Impaired subjective health status in chronic adrenal insufficiency: impact of different glucocorticoid replacement regimens. Eur. J. Endocrinol. 159, 811–817 (2008)CrossRefPubMed B. Bleicken, S. Hahner, M. Loeffler et al., Impaired subjective health status in chronic adrenal insufficiency: impact of different glucocorticoid replacement regimens. Eur. J. Endocrinol. 159, 811–817 (2008)CrossRefPubMed
8.
Zurück zum Zitat S. Hahner, M. Loeffler, M. Fassnacht et al., Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. J. Clin. Endocrinol. Metab. 92, 3912–3922 (2007)CrossRefPubMed S. Hahner, M. Loeffler, M. Fassnacht et al., Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. J. Clin. Endocrinol. Metab. 92, 3912–3922 (2007)CrossRefPubMed
9.
Zurück zum Zitat K. Lovas, J.H. Loge, E.S. Husebye, Subjective health status in Norwegian patients with Addison’s disease. Clin. Endocrinol. (Oxf.). 56, 581–588 (2002)CrossRefPubMed K. Lovas, J.H. Loge, E.S. Husebye, Subjective health status in Norwegian patients with Addison’s disease. Clin. Endocrinol. (Oxf.). 56, 581–588 (2002)CrossRefPubMed
10.
Zurück zum Zitat J. Tiemensma, C.D. Andela, A.A. Kaptein et al., Psychological morbidity and impaired quality of life in patients with stable treatment for primary adrenal insufficiency: cross-sectional study and review of the literature. Eur. J. Endocrinol. 171, 171–182 (2014)CrossRefPubMed J. Tiemensma, C.D. Andela, A.A. Kaptein et al., Psychological morbidity and impaired quality of life in patients with stable treatment for primary adrenal insufficiency: cross-sectional study and review of the literature. Eur. J. Endocrinol. 171, 171–182 (2014)CrossRefPubMed
11.
Zurück zum Zitat K. Lovas, S. Curran, M. Oksnes et al., Development of a disease-specific quality of life questionnaire in Addison’s disease. J. Clin. Endocrinol. Metab. 95, 545–551 (2010)CrossRefPubMed K. Lovas, S. Curran, M. Oksnes et al., Development of a disease-specific quality of life questionnaire in Addison’s disease. J. Clin. Endocrinol. Metab. 95, 545–551 (2010)CrossRefPubMed
12.
Zurück zum Zitat M. Oksnes, S. Bensing, A.L. Hulting et al., Quality of life in European patients with Addison’s disease: validity of the disease-specific questionnaire AddiQoL. J. Clin. Endocrinol. Metab. 97, 568–576 (2012)CrossRefPubMed M. Oksnes, S. Bensing, A.L. Hulting et al., Quality of life in European patients with Addison’s disease: validity of the disease-specific questionnaire AddiQoL. J. Clin. Endocrinol. Metab. 97, 568–576 (2012)CrossRefPubMed
13.
Zurück zum Zitat L. Gagliardi, M.A. Nenke, T.R. Thynne et al., Continuous subcutaneous hydrocortisone infusion therapy in Addison’s disease: a randomized, placebo-controlled clinical trial. J. Clin. Endocrinol. Metab. 99, 4149–4157 (2014)CrossRefPubMed L. Gagliardi, M.A. Nenke, T.R. Thynne et al., Continuous subcutaneous hydrocortisone infusion therapy in Addison’s disease: a randomized, placebo-controlled clinical trial. J. Clin. Endocrinol. Metab. 99, 4149–4157 (2014)CrossRefPubMed
14.
Zurück zum Zitat J. Langenheim, M. Ventz, A. Hinz, M. Quinkler, Modified-release prednisone decreases complaints and fatigue compared to standard prednisolone in patients with adrenal insufficiency. Horm. Metab. Res. 45, 96–101 (2013)PubMed J. Langenheim, M. Ventz, A. Hinz, M. Quinkler, Modified-release prednisone decreases complaints and fatigue compared to standard prednisolone in patients with adrenal insufficiency. Horm. Metab. Res. 45, 96–101 (2013)PubMed
15.
Zurück zum Zitat M. Quinkler, R. Miodini Nilsen, K. Zopf et al., Modified-release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency. Eur. J. Endocrinol. 172, 619–626 (2015)CrossRefPubMed M. Quinkler, R. Miodini Nilsen, K. Zopf et al., Modified-release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency. Eur. J. Endocrinol. 172, 619–626 (2015)CrossRefPubMed
16.
Zurück zum Zitat G. Meyer, A. Hackemann, M. Penna-Martinez, K. Badenhoop, What affects the quality of life in autoimmune Addison’s disease? Horm. Metab. Res. 45, 92–95 (2013)CrossRefPubMed G. Meyer, A. Hackemann, M. Penna-Martinez, K. Badenhoop, What affects the quality of life in autoimmune Addison’s disease? Horm. Metab. Res. 45, 92–95 (2013)CrossRefPubMed
17.
Zurück zum Zitat A.H. Heald, A. Walther, J.R.E. Davis et al., No difference in mood and quality of life in dhea-s deficient adults with addison’s disease vs. type 2 diabetes patients with normal DHEA-S levels: implications for management of these conditions. Front Psychol. 8, 764 (2017)CrossRefPubMedPubMedCentral A.H. Heald, A. Walther, J.R.E. Davis et al., No difference in mood and quality of life in dhea-s deficient adults with addison’s disease vs. type 2 diabetes patients with normal DHEA-S levels: implications for management of these conditions. Front Psychol. 8, 764 (2017)CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat M. Henry, P.S. Wolf, I.L. Ross, K.G. Thomas, Poor quality of life, depressed mood, and memory impairment may be mediated by sleep disruption in patients with Addison’s disease. Physiol. Behav. 151, 379–385 (2015)CrossRefPubMedPubMedCentral M. Henry, P.S. Wolf, I.L. Ross, K.G. Thomas, Poor quality of life, depressed mood, and memory impairment may be mediated by sleep disruption in patients with Addison’s disease. Physiol. Behav. 151, 379–385 (2015)CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat S.R. Bornstein, B. Allolio, W. Arlt et al., Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 101, 364–389 (2016)CrossRefPubMed S.R. Bornstein, B. Allolio, W. Arlt et al., Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 101, 364–389 (2016)CrossRefPubMed
20.
Zurück zum Zitat E.S. Husebye, B. Allolio, W. Arlt et al., Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. J. Intern. Med. 275, 104–115 (2014)CrossRefPubMed E.S. Husebye, B. Allolio, W. Arlt et al., Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. J. Intern. Med. 275, 104–115 (2014)CrossRefPubMed
21.
Zurück zum Zitat H.J. Repping-Wuts, N.M. Stikkelbroeck, A. Noordzij et al., A glucocorticoid education group meeting: an effective strategy for improving self-management to prevent adrenal crisis. Eur. J. Endocrinol. 169, 17–22 (2013)CrossRefPubMed H.J. Repping-Wuts, N.M. Stikkelbroeck, A. Noordzij et al., A glucocorticoid education group meeting: an effective strategy for improving self-management to prevent adrenal crisis. Eur. J. Endocrinol. 169, 17–22 (2013)CrossRefPubMed
22.
Zurück zum Zitat P. Tyrer, S. Cooper, M. Crawford et al., Prevalence of health anxiety problems in medical clinics. J. Psychosom. Res. 71, 392–394 (2011)CrossRefPubMed P. Tyrer, S. Cooper, M. Crawford et al., Prevalence of health anxiety problems in medical clinics. J. Psychosom. Res. 71, 392–394 (2011)CrossRefPubMed
23.
Zurück zum Zitat P.M. Stewart, B.M. Biller, C. Marelli et al., Exploring inpatient hospitalizations and morbidity in patients with adrenal insufficiency. J. Clin. Endocrinol. Metab. 101, 4843–4850 (2016)CrossRefPubMed P.M. Stewart, B.M. Biller, C. Marelli et al., Exploring inpatient hospitalizations and morbidity in patients with adrenal insufficiency. J. Clin. Endocrinol. Metab. 101, 4843–4850 (2016)CrossRefPubMed
24.
Zurück zum Zitat J. Daniels, E. Sheils, A complex interplay: cognitive behavioural therapy for severe health anxiety in Addison’s disease to reduce emergency department admissions. Behav. Cogn. Psychother. 45, 419–426 (2017)CrossRefPubMed J. Daniels, E. Sheils, A complex interplay: cognitive behavioural therapy for severe health anxiety in Addison’s disease to reduce emergency department admissions. Behav. Cogn. Psychother. 45, 419–426 (2017)CrossRefPubMed
25.
Zurück zum Zitat J. Daniels, J.M. Turner-Cobb, Adjuvant psychological therapy in long-term endocrine conditions. Clin. Endocrinol. 86, 772–777 (2017)CrossRef J. Daniels, J.M. Turner-Cobb, Adjuvant psychological therapy in long-term endocrine conditions. Clin. Endocrinol. 86, 772–777 (2017)CrossRef
26.
Zurück zum Zitat S. Hahner, N. Hemmelmann, M. Quinkler et al., Timelines in the management of adrenal crisis-targets, limits and reality. Clin. Endocrinol. (Oxf.). 82, 497–502 (2015)CrossRefPubMed S. Hahner, N. Hemmelmann, M. Quinkler et al., Timelines in the management of adrenal crisis-targets, limits and reality. Clin. Endocrinol. (Oxf.). 82, 497–502 (2015)CrossRefPubMed
27.
Zurück zum Zitat C. Leblicq, D. Rottembourg, J. Deladoey et al., Are guidelines for glucocorticoid coverage in adrenal insufficiency currently followed? J. Pediatr. 158, 492–498 (2011). e1CrossRefPubMed C. Leblicq, D. Rottembourg, J. Deladoey et al., Are guidelines for glucocorticoid coverage in adrenal insufficiency currently followed? J. Pediatr. 158, 492–498 (2011). e1CrossRefPubMed
Metadaten
Titel
Longitudinal AddiQoL scores may identify higher risk for adrenal crises in Addison’s disease
verfasst von
Gesine Meyer
Maike Koch
Eva Herrmann
Jörg Bojunga
Klaus Badenhoop
Publikationsdatum
31.01.2018
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2018
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-017-1513-0

Weitere Artikel der Ausgabe 2/2018

Endocrine 2/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.